These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3770010)

  • 1. Hepatic metabolism of doxorubicin in mice and rats.
    Vrignaud P; Londos-Gagliardi D; Robert J
    Eur J Drug Metab Pharmacokinet; 1986; 11(2):101-5. PubMed ID: 3770010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS).
    Cummings J; Merry S; Willmott N
    Eur J Cancer Clin Oncol; 1986 Apr; 22(4):451-60. PubMed ID: 3460809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.
    Cummings J; Willmott N; More I; Kerr DJ; Morrison JG; Kaye SB
    Biochem Pharmacol; 1987 May; 36(9):1521-6. PubMed ID: 3579988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
    Schaupp CM; White CC; Merrill GF; Kavanagh TJ
    Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.
    Willmott N; Cummings J; Marley E; Smyth JF
    Biochem Pharmacol; 1990 Mar; 39(6):1055-62. PubMed ID: 2322293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
    Booth CL; Brouwer KR; Brouwer KL
    Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The consequences of doxorubicin quinone reduction in vivo in tumour tissue.
    Cummings J; Willmott N; Hoey BM; Marley ES; Smyth JF
    Biochem Pharmacol; 1992 Dec; 44(11):2165-74. PubMed ID: 1472081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.
    Cummings J; Milstead R; Cunningham D; Kaye S
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):991-1001. PubMed ID: 3770056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin.
    Peters JH; Gordon GR; Kashiwase D; Acton EM
    Cancer Chemother Pharmacol; 1981; 7(1):65-9. PubMed ID: 7340990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of fluorescence by anthracycline antibiotics: effects of xanthine oxidase and identification of the nonfluorescent metabolites.
    Dodion P; Bernstein AL; Fox BM; Bachur NR
    Cancer Res; 1987 Feb; 47(4):1036-9. PubMed ID: 3467841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin.
    Weenen H; van Maanen JM; de Planque MM; McVie JG; Pinedo HM
    Eur J Cancer Clin Oncol; 1984 Jul; 20(7):919-26. PubMed ID: 6589165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit.
    Gewirtz DA; Yanovich S
    Biochem Pharmacol; 1987 Jun; 36(11):1793-8. PubMed ID: 3579974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative determination of adriamycin in rat hepatocytes using a volatile extraction buffer, HPLC and fluorescence detection.
    Mahdadi R; Pommery N; Pommery J; Lhermitte M
    Biomed Chromatogr; 1987; 2(3):91-4. PubMed ID: 3507221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hyperthermia on the in vitro metabolism of doxorubicin.
    Dodion P; Riggs CE; Akman SR; Bachur NR
    Cancer Treat Rep; 1986 May; 70(5):625-9. PubMed ID: 3708610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body residue and metabolism of adriamycin and daunorubicin in control and phenobarbital-pretreated mice.
    Bolanowska W; Gessner T
    Xenobiotica; 1982 Feb; 12(2):125-36. PubMed ID: 7090422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative anthracycline metabolism in rats: loss of marcellomycin fluorescence.
    Dodion P; Tamburini JM; Fox BM; Riggs CE; Bachur NR
    Cancer Res; 1986 Jun; 46(6):2714-9. PubMed ID: 3084076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of hepatocyte stimulating activity by T3 and appearance of the activity despite inhibition of DNA synthesis by adriamycin.
    Francavilla A; Ove P; Van Thiel DH; Coetzee ML; Wu SK; DiLeo A; Starzl TE
    Horm Metab Res; 1984 May; 16(5):237-42. PubMed ID: 6376310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
    Cummings J
    J Chromatogr; 1985 Jun; 341(2):401-9. PubMed ID: 4030989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
    van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
    Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
    Cummings J; Stuart JF; Calman KC
    J Chromatogr; 1984 Nov; 311(1):125-33. PubMed ID: 6520153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.